Michael L. Meyers

Michael is a medical oncologist and experienced drug developer who has contributed to the successful development and commercialization of multiple new therapies. Most recently, Michael served as Senior Vice President, Chief Development Officer, and Chief Medical Officer at Syndax Pharmaceuticals, where he led the development of multiple molecules in breast cancer, various immune-oncology indications, acute leukemias, and chronic Graft versus Host Disease.

Prior to joining Syndax, he held a number of senior R&D roles at Johnson & Johnson, including serving as Vice President, of GU Oncology, Compound and Clinical Leader, and Vice President, of Oncology Scientific Innovation in Johnson and Johnson’s London Innovation Centre. Michael led the Compound Development Teams that achieved approvals and successful launches for abiraterone acetate in prostate cancer and for bortezomib in multiple myeloma and non-Hodgkin lymphoma. Michael also led the U.S. Oncology Medical Affairs team at Aventis Pharmaceuticals Inc. and worked in oncology clinical development at the Schering-Plough Research Institute. Prior, he was on the Memorial Sloan Kettering Cancer Center faculty, specializing in Clinical Immunology and melanoma.